Bio

Dr. Wu earned her medical degree and a doctorate in clinical medicine at the West China Medical College in China. She received her first postdoc training at Smidt heart institute of Cedars Sinai medical center and focused on studying the endovascular inflammation and calcium regulation in HFpEF (Heart Failure with Preserved Ejection Fraction) and testing the efficacy of Cardiosphere-derived cells (CDCs) and their secreted exosomes (CDCexo) for heart failure. She comes to the Alexander Lab with expertise in calcium handling and cardiosphere-derived cell-based therapy in rodents models. Dr. Wu is currently leading our research efforts on studying the mechanisms underlying the development of transthyretin cardiac amyloidosis(ATTR). Her work using iPSC and animal models as well as human samples will undoubtedly lead to important insights into this deadly disease and improve outcomes for cardiac amyloid patients.

Professional Education

  • M.D./Ph.D., Sichuan University, West China School of Medicine, Clinical Medicine (2018)

Stanford Advisors

Additional Info

All Publications

  • Rapid 3D bioprinting of a multicellular model recapitulating pterygium microenvironment BIOMATERIALS Zhong, Z., Wang, J., Tian, J., Deng, X., Balayan, A., Sun, Y., Xiang, Y., Guan, J., Schimelman, J., Hwang, H., You, S., Wu, X., Ma, C., Shi, X., Yao, E., Deng, S. X., Chen, S. 2022; 282: 121391

    Abstract

    Pterygium is an ocular surface disorder with high prevalence that can lead to vision impairment. As a pathological outgrowth of conjunctiva, pterygium involves neovascularization and chronic inflammation. Here, we developed a 3D multicellular in vitro pterygium model using a digital light processing (DLP)-based 3D bioprinting platform with human conjunctival stem cells (hCjSCs). A novel feeder-free culture system was adopted and efficiently expanded the primary hCjSCs with homogeneity, stemness and differentiation potency. The DLP-based 3D bioprinting method was able to fabricate hydrogel scaffolds that support the viability and biological integrity of the encapsulated hCjSCs. The bioprinted 3D pterygium model consisted of hCjSCs, immune cells, and vascular cells to recapitulate the disease microenvironment. Transcriptomic analysis using RNA sequencing (RNA-seq) identified a distinct profile correlated to inflammation response, angiogenesis, and epithelial mesenchymal transition in the bioprinted 3D pterygium model. In addition, the pterygium signatures and disease relevance of the bioprinted model were validated with the public RNA-seq data from patient-derived pterygium tissues. By integrating the stem cell technology with 3D bioprinting, this is the first reported 3D in vitro disease model for pterygium that can be utilized for future studies towards personalized medicine and drug screening.

    View details for DOI 10.1016/j.biomaterials.2022.121391

    View details for Web of Science ID 000788717500002

    View details for PubMedID 35101743

https://orcid.org/0000-0003-1020-6232